Editas Medicine Cash Flow Statement
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Editas Medicine free cash flow
In fiscal 2025, Editas Medicine generated -$165.2 million of operating cash flow and spent $607,000 on capital expenditures. That left free cash flow of -$165.8 million, a free-cash-flow margin of -409.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Editas Medicine cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -160.06M | -237.09M | -153.22M | -220.43M | -192.50M | -115.98M | -133.75M | -109.95M | -120.32M | -97.18M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 5.28M | 5.81M | 6.06M | 6.34M | 5.05M | 3.96M | 2.83M | 3.25M | 2.68M | 1.20M |
| Stock-Based Compensation | 10.00M | 21.42M | 19.80M | 29.29M | 43.40M | 23.16M | 27.24M | 26.60M | 23.36M | 16.88M |
| Change in Working Capital | -29.84M | -11.16M | -4.93M | -3.98M | -14.33M | -103.89M | 56.44M | 22.94M | 78.99M | 15.65M |
| Operating Cash Flow | -165.24M | -210.28M | -132.18M | -177.35M | -163.80M | -179.84M | -40.67M | -45.71M | -9.42M | -50.25M |
| Capital Expenditures | -607.00K | -8.83M | -4.72M | -4.12M | -7.98M | -7.16M | -6.17M | -4.75M | -2.06M | -3.49M |
| Investing Cash Flow | 138.67M | 162.15M | -3.73M | 114.07M | -54.47M | -140.52M | 12.25M | -53.09M | -183.81M | -3.47M |
| Debt Issued | — | 57.00M | — | — | — | — | — | — | — | — |
| Debt Repaid | -2.87M | 0 | — | — | — | — | — | — | — | — |
| Financing Cash Flow | 40.47M | 56.03M | 118.04M | 1.28M | 282.11M | 224.12M | 131.82M | 86.94M | 154.53M | 97.16M |
| Net Change in Cash | 13.90M | 7.89M | -17.87M | -62.00M | 63.84M | -96.24M | 103.41M | -11.85M | -38.69M | 43.44M |
| Free Cash Flow | -165.85M | -219.11M | -136.90M | -181.47M | -171.78M | -187.00M | -46.84M | -50.46M | -11.48M | -53.74M |
This table shows 10 annual periods of Editas Medicine's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EDIT's reporting calendar. What is a cash flow statement?